Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982928 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL7736439 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL13262186 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL8345 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL16212282 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL24141674 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL5717505 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL12041986 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| SCHEMBL5982921 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1ALBLMNASMN1; SMN2 | |
| Phosphoric Acid SCHEMBL8409010 | 0.95 | DNMT1 (0.58) | DNMT1ADRB1ALBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1085 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333699-A1 | METHOD FOR PREPARATION OF CYTOTOXIC T LYMPHOCYTES WITH BROAD TUMOUR-SPECIFIC REACTIVITY AND CHARACTERISTICS OF EARLY DIFFERENTIATION CELLS | CYTOVAC AS (DK) | 2025-10-30 | — | — | US | claimed |
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| WO-2025009968-A1 | METHODS FOR SPECIFIC QUANTITATION OF THE INDUCIBLE HIV RESERVOIR | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2025-01-09 | — | — | WO | claimed |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. | 2025-01-02 | — | — | US | claimed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | claimed |
| US-20240269157-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2024-08-15 | — | — | US | claimed |
| EP-4404969-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| EP-4359510-A1 | METHOD FOR PREPARATION OF CYTOTOXIC T LYMPHOCYTES WITH BROAD TUMOUR-SPECIFIC REACTIVITY AND CHARACTERISTICS OF EARLY DIFFERENTIATION CELLS | CytoVac A/S (DK) | 2024-05-01 | — | — | EP | claimed |
| WO-1994019362-A1 | 4-ETHOXY 5-FLUORO 2'DEOXYURIDINE | CITY OF HOPE (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1992014729-A1 | ANTIVIRAL 1,3-DIOXOLANE NUCLEOSIDES AND SYNTHESIS THEREOF | EMORY UNIVERSITY (US) | 1992-09-03 | — | — | WO | claimed |
| US-5137724-A | Active ingredient and potentiating ingredient; cytidine and vridine derivatives | STICHTING REGA VZW (BE) | 1992-08-11 | — | — | US | claimed |
| EP-0160079-B1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER, Sheldon B. (US) | 1990-01-31 | — | — | EP | claimed |
| US-4894364-A | ANTITUMOR AGENTS | HALOGENETICS, INC. | 1990-01-16 | — | — | US | claimed |
| EP-0258412-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER, Sheldon B. (US) | 1988-03-09 | — | — | EP | claimed |
| WO-1987004929-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER SHELDON B | 1987-08-27 | — | — | WO | claimed |
| EP-0160079-A4 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1986-05-14 | — | — | EP | claimed |
| EP-0160079-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1985-11-06 | — | — | EP | claimed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | DNMT1 111/4885ADRB1 2700/4885ALB 1096/4885 |
| US-20240269157-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | DNMT1 187/4885ADRB1 4011/4885ALB 2300/4885 |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | NFATC1, MKI67, ICOS | DNMT1 52/4885ADRB1 4031/4885ALB 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.